Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults.

[1]  R. Janssen,et al.  Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. , 2018, Vaccine.

[2]  Jiaquan Xu,et al.  Deaths: Final Data for 2014. , 2016, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[3]  M. Kainer,et al.  Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013. , 2016, MMWR. Morbidity and mortality weekly report.

[4]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials , 2015, Journal of Nuclear Cardiology.

[5]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[6]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[7]  Joel Stein,et al.  Heart Disease and Stroke Statistics – At-a-Glance , 2015 .

[8]  R. Janssen,et al.  Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. , 2013, Vaccine.

[9]  E. De Gregorio,et al.  Vaccine Adjuvants: Mode of Action , 2013, Front. Immunol..

[10]  K. Kowdley,et al.  Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin , 2012, Hepatology.

[11]  P. D. de Groot,et al.  The significance of autoantibodies against β2-glycoprotein I. , 2012, Blood.

[12]  J. Langley,et al.  Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. , 2012, Vaccine.

[13]  I. Živković,et al.  Vaccine model of antiphospholipid syndrome induced by tetanus vaccine , 2012, Lupus.

[14]  J. Langley,et al.  Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed , 2012 .

[15]  E. Feller,et al.  Hepatitis B in the United States: ongoing missed opportunities for hepatitis B vaccination, evidence from the Behavioral Risk Factor Surveillance Survey, 2007 , 2012, Infection.

[16]  E. Jongert,et al.  Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. , 2010, Vaccine.

[17]  L. Dickinson,et al.  Physician practices regarding adult hepatitis B vaccination: a national survey. , 2009, American journal of preventive medicine.

[18]  S. Čučnik,et al.  Anti‐phospholipid antibodies following vaccination with recombinant hepatitis B vaccine , 2005, Clinical and experimental immunology.

[19]  T. Giese,et al.  Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1 , 2002, The Journal of Immunology.

[20]  H. Margolis,et al.  Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. , 1998, American journal of preventive medicine.

[21]  M. Osterholm,et al.  Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. , 1993, JAMA.

[22]  A. Hammond,et al.  Immunization against hepatitis B-what can we expect?: Results of a survey of antibody response to immunization in persons ‘at risk’ of occupational exposure to hepatitis B , 1990, Epidemiology and Infection.

[23]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.